BioXcel Therapeutics, Inc.
BTAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $14,196 | $9,813 | $18,173 |
| - Cash | $37,320 | $17,435 | $31,013 | $29,854 |
| + Debt | $92,302 | $108,685 | $105,909 | $102,947 |
| Enterprise Value | – | $105,446 | $84,709 | $91,266 |
| Revenue | $98 | $120 | $168 | $366 |
| % Growth | -18.3% | -28.6% | -54.1% | – |
| Gross Profit | $12 | $13 | $154 | -$466 |
| % Margin | 12.2% | 10.8% | 91.7% | -127.3% |
| EBITDA | -$26,463 | -$14,890 | -$3,185 | -$6,750 |
| % Margin | -27,003.1% | -12,408.3% | -1,895.8% | -1,844.3% |
| Net Income | -$30,911 | -$19,187 | -$7,254 | -$10,859 |
| % Margin | -31,541.8% | -15,989.2% | -4,317.9% | -2,966.9% |
| EPS Diluted | -2.18 | -2.45 | -1.5 | -3.57 |
| % Growth | 11% | -63.3% | 58% | – |
| Operating Cash Flow | -$18,787 | -$12,575 | -$12,043 | -$14,809 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$18,787 | -$12,575 | -$12,043 | -$14,809 |